Back to results
US 11,535,676 B2Granted
Anti-mullerian hormone receptor binding peptides
OwnerLaura Dettiinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerLaura Dettiinventor
Estimating the term…
Disclosed are compositions and methods including Anti-Müllerian Hormone (AMH) receptor binding peptides. The AMH receptor binding peptides can be used, for example, to modify the activity of the AMH receptor. For example, the AMH receptor binding peptides can activate the AMH receptor, such as the AMH receptor 2, thereby mimicking the function of AMH. In other examples, the AMH receptor binding peptides function as AMH receptor antagonists, thereby interfering with the function of endogenous AMH. By modifying the activity of the AMH receptor, the peptides have multiple applications, including for example modification of treatment of precocious puberty in females, delay of natural menopause, preservation of ovarian follicular reserve, contraception, fertility preservation after ovarian cortex transplant, treatment of endometriosis, treatment of cancer and/or cancer prevention, and treatment of polycystic ovary syndrome (PCOS).
An anti-Mullerian hormone receptor 2 (AMH-R2) binding peptide or functional fragment thereof, the AMH-R2 binding peptide or functional fragment thereof comprising any one of the amino acid sequences set forth as SEQ ID NOS:
A composition for use in stimulating an Anti-Mullerian Hormone receptor 2 (AMH-R2), the composition comprising an AMH-R2 binding peptide or functional fragment thereof, the AMH-R2 binding peptide or functional fragment thereof comprising any one of the amino acid sequences set forth as SEQ ID NOS:
A method of modulating folliculogenesis in a subject, the method comprising administering an effective amount an anti-Mullerian hormone receptor 2 (AMH-R2) binding peptide or functional fragment thereof to the subject, the AMH-R2 binding peptide or functional fragment thereof comprising any one of the amino acid sequences set forth as SEQ ID NOS:
A method of inhibiting premature follicle activation in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-Mullerian hormone receptor 2 (AMH-R2) binding peptide or functional fragment thereof, the AMH-R2 binding peptide or functional fragment thereof comprising any one of the amino acid sequences set forth SEQ ID NOS:
Dependencies are inferred from the claim text.